Company intelligence / Profile preview

ErlySign

Nagpur, Maharashtra, India

Ownership: Private
Employees: ~25
Development stage: Other

Overview

ErlySign is a biotechnology company focused on the early detection of cancer through non-invasive, saliva-based diagnostic tests. The company utilizes a proprietary platform that identifies specific biomarkers to detect oral and lung cancers at an early stage, significantly improving the chances of successful treatment. Their technology is designed to be affordable and accessible, aiming to replace or supplement traditional, more invasive screening methods. ErlySign gained significant public attention through its appearance on Shark Tank India, where it secured investment to scale its diagnostic solutions.

Therapeutic areas: Oncology
Modalities: DiagnosticBiomarker-based assay
Industry: Molecular Diagnostics

Beyond the preview

Go deeper on ErlySign.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ErlySign.

Explore the full profile